Oncology

AmerisourceBergen Rep Previews the Year Ahead for Biosimilars: What’s Coming Down the Pipeline in 2022?

January 24th 2022

By Tony Hagen

Sean McGowan, senior director of Biosimilars for AmerisourceBergen, forecasts potential biosimilar approvals and launches in 2022 as well as offers insights into how emerging biosimilars will impact the market and pricing in the coming years during an interview.

Phase 3 Study Shows BI Bevacizumab Biosimilar Comparable to Reference Product

January 19th 2022

By Meir Rinde, MS

Article

Two biosimilars, Pfizer’s Zirabev and Amgen’s Mvasi, have been approved for indications including unresectable, locally advanced NSCLC and recurrent or metastatic nonsquamous NSCLC. BI 695502 is no longer under development by Boehringer Ingelheim.

Real-world Study Sees Adoption of Mvasi by US Oncologists for Metastatic CRC

January 18th 2022

By Deana Ferreri, PhD

Article

Records show the biosimilar for bevacizumab was used to treat both new patients and those already receiving care with the reference product.

International Biosimilars Trade Group Appoints New Leadership for 2022

January 15th 2022

By Tony Hagen

Article

The International Generic and Biosimilar Medicines Association has appointed a veteran member, Vivian Frittelli, MBA, ACIS, to take over as chair.

Michigan Trade Group Outlines Best Practices for Biosimilar Adoption

January 13th 2022

By Tony Hagen

Article

Ford Motor saved $5 million by switching patients to 5 biosimilars, and other manufacturers and employers in Michigan have achieved good results with switching programs, the Economic Alliance of Michigan reports.

Amgen CEO Touts Potential for Doubling in Biosimilar Revenue

January 11th 2022

By Tony Hagen

Article

Amgen Chairman and CEO Robert Bradway touted the potential of 11 biosimilars anticipated to be driving revenues for the company by 2030.

Developers Advised to Challenge Regulatory Standards to Speed Development of Biosimilars

January 11th 2022

By Meir Rinde, MS

Article

In a recent paper, Sarfaraz K. Niazi, PhD summarizes some of his central ideas on the relevance of FDA biosimilar testing standards.

In India, Patient Advocates Lobby for Modernized Biosimilar Development Standards

January 8th 2022

By Tony Hagen

Article

In India, an emphasis on outdated biosimilar testing has restricted market entry of these products and discouraged manufacturers, patient advocates contend.

Study: Epoetin Alfa Biosimilar Candidate Equivalent to Epogen

January 5th 2022

By Deana Ferreri, PhD

Article

A comparative study of PanGen Biotech’s epoetin alfa biosimilar candidate PDA10 and the reference product, Retacrit, demonstrated comparable efficacy and safety.

Biosimilar Savings Through 2025 Could Total $38.4 Billion

January 4th 2022

By Tony Hagen

Article

Savings from adalimumab biosimilars, which won't enter the US market until 2023, account for a significant share of the total, investigators said.